Menu

Sign in

Sign in

For suppliers Contact us

Homepage > Company > Media > Pharma News

Pharma News

FDA warns vs fake versions of popular medicines

FDA warns vs fake versions of popular medicines

MANILA, Philippines - counterfeit versions of some popular over-the-counter pain relievers and flu medicines are circulating in the market, the Food and Drug Administration (FDA) reported. ...

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Japan's Eisai inks $2 B oncology deal with China-based startup Bliss Biopharma

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

Cognixion receives FDA Breakthrough Device Designation for assisted communication device

Cognixion, a developer of non-invasive Brain-Computer Interface (BCI) and Augmented Reality (AR) technology, has announced that the US Food and Drug Administration (FDA) has granted its device Brea...

EMA to review CTIS transparency rules

EMA to review CTIS transparency rules

Public consultation seeks the best methods for balancing transparency with confidentiality in the EU Clinical Trials Information System, says the European Medicines Agency. ...

Lupin to acquire French firm Medisol for around Rs 160 crore

Lupin to acquire French firm Medisol for around Rs 160 crore

Pharmaceuticals firm Lupin Ltd on Friday said it will fully acquire French pharmaceutical company Medisol for 18 million euros (over Rs 160 crore).

Boehringer Ingelheim Earns Breakthrough Therapy Designation for Pustular Psoriasis Drug

Boehringer Ingelheim Earns Breakthrough Therapy Designation for Pustular Psoriasis Drug

The FDA granted breakthrough therapy designation to Boehringer Ingelheim’s Spevigo (spesolimab) as a treatment to prevent flares in adults with generalized pustular psoriasis (GPP). ...

Vertex secures FDA clearance for infants’ cystic fibrosis therapy

Vertex secures FDA clearance for infants’ cystic fibrosis therapy

Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for KALYDECO (ivacaftor) to treat children with cystic fibrosis (CF) aged between one and four months. ...

FDA Approves First-Ever RSV Vaccine After Brutal 2022 Season

FDA Approves First-Ever RSV Vaccine After Brutal 2022 Season

The Food and Drug Administration approved a first-of-its-kind RSV vaccine by pharmaceutical company GlaxoSmithKline for older adults on Wednesday, in time to help the U.S. combat RSV infections and...

Sun Pharma’s Deuruxolitinib IND Placed on Partial Clinical Hold

Sun Pharma’s Deuruxolitinib IND Placed on Partial Clinical Hold

The FDA has placed a partial clinical hold on Sun Pharma’s IND application for Deuruxolitinib (CTP-543), which was being studied in patients with alopecia areata, an autoimmune disease that inclu...

Merck agrees to build bioprocessing production plant in South Korea

Merck agrees to build bioprocessing production plant in South Korea

Merck also intends to forge partnerships in the field of bio-research with major Korean universities.

Alzheimer’s drug developed by Lilly slows cognitive decline by 35 pct

Alzheimer’s drug developed by Lilly slows cognitive decline by 35 pct

An experimental Alzheimer’s drug developed by Eli Lilly and Co slowed cognitive decline by 35 percent in a closely watched late-stage trial, the company said on Wednesday, raising hopes for a sec...

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

Sanofi has signed an exclusive worldwide licensing agreement with Maze Therapeutics for its glycogen synthase 1 (GYS1) programme, including a lead candidate for Pompe disease and other glycogen sto...

12 3 4 5

0 items in Cart

Cart Subtotal:

You will be able to Pay Online or Request a Quote

We use "cookies* to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies